Pheochromocytoma (PCC) and paraganglioma (PGL), jointly referred to as PPGLs, arise from neural crest cells and can develop either in the adrenal medulla or in extra-adrenal paraganglionic tissues \[[@B1]\]. These are rare tumors, with an incidence of 2 to 8 per million \[[@B2]\]. They occur in 0.2% to 0.6% of patients with hypertension and are generally thought to account for up to 5% of adrenal incidentalomas \[[@B3][@B4]\]. Although the prevalence of PPGLs might vary across populations, nationwide epidemiological data on PPGLs are lacking in most countries.

In Korea, epidemiological research on PPGLs has been scarce. A single-center study in 2013 reported the prevalence of PCC among adrenal incidentalomas to be 7.2% \[[@B5]\]. However, no nationwide report has investigated the epidemiology of PPGLs in Korea. In 2018, the Korean Endocrine Society released the Korean Endocrine Rare Disease Fact Sheet 2018 \[[@B6]\]. As an extension of this fact sheet, in this issue of *Endocrinology and Metabolism*, Kim et al. \[[@B7]\] investigated the incidence, prevalence, complications, metastasis, and mortality of PPGLs based on data from the National Health Insurance Service between 2003 and 2014. The operational definition of PPGLs was subjects with International Classification of Diseases, 10th Revision (ICD-10) diagnostic codes for adrenal tumors or PGL, and the definition was limited to those who underwent biochemical tests and surgery. Additionally, subjects with diagnostic codes for aldosteronism, Cushing syndrome, and adrenal cortical carcinoma were excluded.

In total, 1,048 subjects were included. The overall prevalence of PPGLs was 2.13 per 100,000 persons. The overall age-standardized incidence rate was 0.18 per 100,000 person-years. Malignant PPGLs accounted for 17.7% of cases. This was the first nationwide population-based epidemiological study of PPGLs to be conducted in Asia. Previously, Beard et al. \[[@B8]\] reported its incidence to be 0.8 per 100,000 person-years. Another analysis of national cancer registry data from Sweden reported its incidence to be 0.21 per 100,000 person-years \[[@B9]\]. Recently, a Dutch group reported the incidence of PCC and PGL to be 0.46 and 0.11 per 100,000 person-years, respectively, in 2011 to 2015 \[[@B10]\]. That study involved an analysis of the Dutch pathology registry. Compared to the findings of previous studies, the incidence rate in Korea seems to be similar or slightly lower.

Two previous single-center studies have investigated the rate of metastasis and the prognosis of PPGLs in Korea, and found that 29 of 223 (13.0%) and 33 of 299 (11.0%) of cases were metastatic, respectively \[[@B11][@B12]\]. In comparison to those two previous studies, this study reported a slightly higher rate of malignancy, which might have resulted from the operational definition, as cases were not confirmed by pathologic results.

Kim et al. \[[@B7]\] also evaluated the prognosis of PPGLs. The 5-year survival rates for non-metastatic and metastatic PPGLs at diagnosis were 97% and 84%, respectively. Catecholamine excess, local growth, and metastatic disease all contributed to increased morbidity and mortality in patients with PPGL. However, mortality was found to be caused mainly by metastatic disease \[[@B13]\]. Additionally, in this study, metastatic PPGLs at diagnosis or during the follow-up period were associated with a 2.40-fold higher risk of mortality than non-metastatic PPGLs, adjusted for age, sex, cerebrovascular diseases, cardiovascular disease, diabetes mellitus, and fractures.

In contrast to previously published single-center reports on PPGLs, a rare type of endocrine tumor, it is noteworthy that this study used national data, even though there may have been some inevitable limitations due to the use of a database containing diagnostic codes without pathological confirmation. This study provides an overview of epidemiology of PPGLs in Korea and further encourages other researchers to conduct epidemiological analyses of rare endocrine diseases. Furthermore, this epidemiological study might provide a basis for additional clinical and experimental research on PPGLs.
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